PMID- 35685378
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 16
DP  - 2022
TI  - First Real-World, Multicenter, Post-Marketing, Retrospective Study of 
      Dexamethasone Intraocular Suspension for Inflammation After Cataract Surgery.
PG  - 1783-1794
LID - 10.2147/OPTH.S357267 [doi]
AB  - PURPOSE: To evaluate dexamethasone intraocular suspension 9% (intraocular DXM) in 
      real-world clinical use to manage inflammation associated with cataract surgery. 
      SETTING: Patients who underwent cataract surgery and received intraocular DXM at 
      22 outpatient eye surgery centers in the US. DESIGN: Retrospective, observational 
      chart review. METHODS: Records of all patients who received intraocular DXM from 
      March to December 2019 at participating centers were reviewed. MAIN OUTCOME 
      MEASURES: Outcomes included anterior chamber cell (ACC) grades, anterior chamber 
      flare (ACF) grades, and visual acuity, as well as intraocular pressure (IOP) and 
      adverse events (AEs) at postoperative days (PODs) 1, 8, 14, 30. Descriptive 
      statistics were generated. RESULTS: The study population included 527 patients 
      (641 eyes), with glaucoma history in 66 patients (80 eyes). Among eyes with 
      recorded ACC grades, the percentage with grade 0 increased from 40% at POD 1 to 
      89.7% at POD 30, with similar results in eyes with glaucoma history. Among eyes 
      with recorded ACF grades, the percentage with grade 0 increased from 78.4% at POD 
      1 to 97.1% at POD 30. At POD 30, 96.6% eyes with recorded results achieved target 
      acuity. Mean IOP was 18.6 mmHg at POD 1 but declined to </=15.2 mmHg thereafter. 
      Investigators reported 22 AEs in 20 patients, all reported mild or moderate, the 
      most common: IOP increase (7 events). CONCLUSION: Patients undergoing cataract 
      surgery and treated with intraocular DXM showed favorable inflammatory and visual 
      outcomes, without unanticipated safety problems, consistent with results of 
      previous controlled clinical trials.
CI  - (c) 2022 Bacharach et al.
FAU - Bacharach, Jason
AU  - Bacharach J
AD  - North Bay Eye Associates Petaluma, Petaluma, CA, USA.
FAU - McCabe, Cathleen
AU  - McCabe C
AD  - The Eye Associates, Bradenton, FL, USA.
FAU - Jackson, Mitchell
AU  - Jackson M
AUID- ORCID: 0000-0002-7591-921X
AD  - Jacksoneye Ophthalmology, Lake Villa, IL, USA.
FAU - Rao, Sanjay
AU  - Rao S
AD  - DeKalb Eye Consultants - Hauser-Ross Eye Institute, Sycamore, IL, USA.
FAU - Singh, I Paul
AU  - Singh IP
AD  - The Eye Centers of Racine & Kenosha, Racine, WI, USA.
FAU - Heersink, Sebastian
AU  - Heersink S
AD  - Eye Center South, Dothan, AL, USA.
FAU - Radcliffe, Nathan
AU  - Radcliffe N
AUID- ORCID: 0000-0003-3976-6831
AD  - New York Eye Surgery Center, Bronx, NY, USA.
FAU - Weinstock, Robert
AU  - Weinstock R
AD  - The Eye Institute of West Florida, Largo, FL, USA.
FAU - Paggiarino, Dario
AU  - Paggiarino D
AD  - EyePoint Pharmaceuticals, Watertown, MA, USA.
FAU - Patel, Keyur
AU  - Patel K
AD  - EyePoint Pharmaceuticals, Watertown, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20220603
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC9172921
OTO - NOTNLM
OT  - cataract surgery
OT  - corticosteroids
OT  - dexamethasone
OT  - inflammation
OT  - intraocular suspension
OT  - ocular drug delivery systems
COIS- Jason Bacharach is a consultant and speaker for EyePoint. Cathleen McCabe reports 
      grants, personal fees from Alcon, during the conduct of the study; grants and/or 
      personal fees from Alcon, Bausch and Lomb, Novartis, Omeros, Ocular Therapeutix, 
      EyePoint, Allergan, Imprimis, Dompe, Johnson and Johnson Vision, and Science 
      Based Health, outside the submitted work. Mitchell Jackson is a consultant and 
      speaker for EyePoint, Omeros, and Ocular Therapeutix. Sebastian Heersink received 
      research support from EyePoint for conducting this study. He also reports grants 
      and/or personal fees from Alcon, Allergan, Eyepoint, Glaukos, Genentech, Johnson 
      and Johnson, Iridex, Ivantis, Kala, Lenstec, grants from and ownership for 
      Lunovus, grants from Nicox, Rayner, Sight Sciences, and Zeiss, during the conduct 
      of the study. Sanjay Rao received research support from EyePoint for conducting 
      this study. Nathaniel Radcliffe is a consultant for CATS, LLC, Allergan, Alcon, 
      Novartis, Eyenovia, Lumenis, Equinox, Iridex, Aerie, Bausch and Lomb, BVI, 
      EyePoint, Ivantis, Glaukos, Alimera, New World Medical, Ocular Therapeutics, 
      Kala, SpyGlass, Sight Science, Thea, Reichert, Shire, Carl Zeiss Meditec, and 
      Omeros; and a speaker for Allergan, Lumenis, Iridex, Aerie, Bausch and Lomb, New 
      World Medical, and Sight Science; and has stock or stock options in Equinox, 
      Sight Sciences, SpyGlass, Ivantis, ELT Sight, CATS, LLC, and Vialase. I Paul 
      Singh is a speaker for EyePoint, B+L, Kala, Ocular Therapeutix, Glaukos, Alcon, 
      Sight Sciences, New World Medical, Elios, Nicox, and iStar Medical; consulting 
      for Imprimus, outside the submitted work. Robert Weinstock is a consultant for 
      EyePoint, Alcon, Bausch and Lomb, Johnson and Johnson, and Lensar. Dario 
      Paggiarino and Keyur Patel are employees of EyePoint Pharmaceuticals, Watertown, 
      Massachusetts, USA. The authors report no other conflicts of interest in this 
      work.
EDAT- 2022/06/11 06:00
MHDA- 2022/06/11 06:01
PMCR- 2022/06/03
CRDT- 2022/06/10 02:29
PHST- 2022/01/20 00:00 [received]
PHST- 2022/05/23 00:00 [accepted]
PHST- 2022/06/10 02:29 [entrez]
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/06/11 06:01 [medline]
PHST- 2022/06/03 00:00 [pmc-release]
AID - 357267 [pii]
AID - 10.2147/OPTH.S357267 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2022 Jun 3;16:1783-1794. doi: 10.2147/OPTH.S357267. eCollection 
      2022.